Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

HIV Infections Clinical Trial

Official title:

Comparison Study of Liposomal Doxorubicin With or Without Bleomycin and Vincristine for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00001059
• Other study ID #: ACTG 286
• Secondary ID: 11262
• Status: Completed
• Phase: Phase 2
• First received: November 2, 1999
• Last updated: April 13, 2012
• Est. completion date: August 1998

Study information

• Verified date: April 2012
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone or in combination with bleomycin and vincristine in the long-term treatment of AIDS-related Kaposi's sarcoma. To determine whether the 3-drug combination enhances progression-free survival and quality of life.

Liposomal formulations of chemotherapeutic agents increase drug accumulation in tumors, which permits disease palliation at relatively low doses and thus decreases some of the dose-limiting toxicity. Multi-agent therapy is considered to be more effective than single-agent therapy; therefore, DOX-SL will be combined with bleomycin and vincristine.

Description:

Liposomal formulations of chemotherapeutic agents increase drug accumulation in tumors, which permits disease palliation at relatively low doses and thus decreases some of the dose-limiting toxicity. Multi-agent therapy is considered to be more effective than single-agent therapy; therefore, DOX-SL will be combined with bleomycin and vincristine.

Patients are randomized to receive intravenous DOX-SL alone or in combination with vincristine/bleomycin every 2 weeks. Filgrastim ( granulocyte colony-stimulating factor; G-CSF ) may be given as needed for neutropenia.

AS PER AMENDMENT 11/7/96: Based on interim review data, it is recommended that subjects receiving DOX-SL plus vincristine/bleomycin have vincristine/bleomycin discontinued and receive DOX-SL alone unless, in the opinion of the treating physician, they are benefitting from the DOX-SL plus vincristine/bleomycin regimen.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: August 1998
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

Concurrent Medication:

Allowed:

• G-CSF.

• Licensed or Treatment IND-approved antiretrovirals ( AZT, ddI, ddC, d4T ).

• PCP prophylaxis (required if CD4 count < 200 cells/mm3).

• Chemoprophylaxis or maintenance for bacterial infections, candidiasis, MAC, and herpes simplex.

• Up to 14 days of metronidazole.

• Recombinant erythropoietin.

Patients must have:

• Documented HIV infection.

• Advanced stage Kaposi's sarcoma.

• No active acute opportunistic infection.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Significant pulmonary insufficiency (unless due to pulmonary KS).

• Significant cardiac insufficiency.

• Other active malignancies except for basal or squamous cell carcinoma of the skin or in situ cervical cancer.

• Grade 2 or worse peripheral neuropathy.

• Altered mental status that prevents informed consent.

• Active Mycobacterium tuberculosis.

• Hypersensitivity or allergic reaction to any study drugs or E. coli-derived medications such as filgrastim (G-CSF).

Concurrent Medication:

Excluded:

• GM-CSF.

• Drugs associated with peripheral neuropathy (other than approved antiretrovirals and vincristine).

• Multi-drug therapy for active Mycobacterium tuberculosis (although isoniazid and pyridoxine is allowed as treatment for a positive PPD, with permission of study chair).

Concurrent Treatment:

Excluded:

• Radiation therapy to study marker lesions.

Patients with the following prior condition are excluded:

• Neuropsychiatric history.

Prior Medication:

Excluded:

• Any anti-KS therapy within 21 days prior to study entry.

• Prior systemic therapy with any anthracycline (including liposomal anthracyclines), vincristine, or bleomycin.

• Any investigational drug (other than those available through Treatment IND and used for FDA-sanctioned purposes) within 14 days prior to study entry.

PER AMENDMENT 11/29/95:

• No more than 2 cycles of any systemic chemotherapy for Kaposi's sarcoma.

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections
• Sarcoma
• Sarcoma, Kaposi

Intervention

Drug:
• Doxorubicin hydrochloride (liposomal)

• Filgrastim

• Bleomycin sulfate

• Vincristine sulfate

Locations

Country	Name	City	State
United States	University of Colorado Hospital CRS	Aurora	Colorado
United States	Alabama Therapeutics CRS	Birmingham	Alabama
United States	Beth Israel Deaconess - East Campus A0102 CRS	Boston	Massachusetts
United States	Bmc Actg Crs	Boston	Massachusetts
United States	Massachusetts General Hospital ACTG CRS	Boston	Massachusetts
United States	SUNY - Buffalo, Erie County Medical Ctr.	Buffalo	New York
United States	Northwestern University CRS	Chicago	Illinois
United States	Rush Univ. Med. Ctr. ACTG CRS	Chicago	Illinois
United States	Queens Med. Ctr.	Honolulu	Hawaii
United States	Univ. of Hawaii at Manoa, Leahi Hosp.	Honolulu	Hawaii
United States	Indiana Univ. School of Medicine, Infectious Disease Research Clinic	Indianapolis	Indiana
United States	UCLA CARE Center CRS	Los Angeles	California
United States	USC CRS	Los Angeles	California
United States	Univ. of Miami AIDS CRS	Miami	Florida
United States	Memorial Sloan-Kettering Cancer Ctr.	New York	New York
United States	Ucsf Aids Crs	San Francisco	California
United States	Washington U CRS	St. Louis	Missouri

Sponsors (3)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Amgen, Sequus Pharmaceuticals

Country where clinical trial is conducted

United States, 

References & Publications (1)

Mitsuyasu R, et al. Comparison study of liposomal doxorubicin (DOX) alone or with bleomycin and vincristine (DBV) for treatment of advanced AIDS-associated Kaposi's sarcoma (AIDS-KS): AIDS Clinical Trial Group (ACTG) protocol 286 (meeting abstract). Proc Annu Meet Am Soc Clin Oncol. 1997;16:A191

External Links

•   Click here for more information about Doxorubicin hydrochloride (liposomal)